Tumor necrosis factor-α 238 G/A polymorphism and risk of hepatocellular carcinoma: Evidence from a meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 5, 2013, Pages 3275-3279

  Cheng, Ke ^a   Zhao, Yu Jun ^a   Liu, Lian ^a   Wan, Jing Jing ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Meta analysis; Single nucleotide polymorphism; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; META ANALYSIS; PROGNOSIS; RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880354650     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.5.3275     Document Type: Article

References (35)

1. Aggarwal BB, Gupta SC, Kim JH (2012). Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood, 119, 651-65.
2. Bridges JF, Joy SM, Gallego G, et al (2011). Needs for hepatocellular carcinoma control policy in the Asia-Pacific region. Asian Pac J Cancer Prev, 12, 2585-91.
3. Chen X, Zhang L, Chang Y, et al (2011). Association of TNFalpha genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a Han Chinese population. Int J Biol Markers, 26, 181-7.
4. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
5. El-Serag HB (2011). Hepatocellular carcinoma. N Engl J Med, 365, 1118-27.
6. Falvo JV, Tsytsykova AV, Goldfeld AE (2010). Transcriptional control of the TNF gene. Curr Dir Autoimmun, 11, 27-60.
7. Fan W, Maoqing W, Wangyang C, et al (2011). Relationship between the polymorphism of tumor necrosis factoralpha- 308 G>A and susceptibility to inflammatory bowel diseases and colorectal cancer: a meta-analysis. Eur J Hum Genet, 19, 432-7.
8. Harkisoen S, Arends JE, van Erpecum KJ, et al (2012). Hepatitis B viral load and risk of HBV-related liver disease: from East to West? Ann Hepatol, 11, 164-71.
9. Heneghan MA, Johnson PJ, Clare M, et al (2003). Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int J Gastrointest Cancer, 34, 19-26.
10. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
11. Huang HL, Xie JS, Huang ZS, et al (2007). The Relationship of Polymorphism of Tulnor Necrosis Factor-Ot Gene Promoter- 238G/A with Prhnary Hepatic Carcinoma in Patients. Progress Anatomical Sci, 13, 11-3.
12. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
13. Jeng JE, Tsai JF, Chuang LY, et al (2007). Tumor necrosis factoralpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia, 9, 987-92.
14. Jeng JE, Tsai HR, Chuang LY, et al (2009). Independent and additive interactive effects among tumor necrosis factoralpha polymorphisms, substance use habits, and chronic hepatitis B and hepatitis C virus infection on risk for hepatocellular carcinoma. Medicine (Baltimore), 88, 349-57.
15. Jung KW, Ha E, Yu GI, et al (2009). TNFalpha promoter polymorphism is a risk factor for susceptibility in hepatocellular carcinoma in Korean population. Clin Chim Acta, 407, 16-9.
16. Kummee P, Tangkijvanich P, Poovorawan Y, et al (2007). Association of HLA-DRB1*13 and TNF-αlpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat, 14, 841-8.
17. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
18. Marcos M, Gomez-Munuera M, Pastor I, et al (2009). Tumor necrosis factor polymorphisms and alcoholic liver disease: a HuGE review and meta-analysis. Am J Epidemiol, 170, 948-56.
19. Mocellin S, Nitti D (2008). TNF and cancer: the two sides of the coin. Front Biosci, 13, 2774-83.
20. Niro GA, Fontana R, Gioffreda D, et al (2005). Tumor necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection. Liver Int, 25, 1175-81.
21. Postal M, Appenzeller S (2011). The role of Tumor Necrosis Factor-alpha (TNF-αlpha) in the pathogenesis of systemic lupus erythematosus. Cytokine, 56, 537-43.
22. Qidwai T, Khan F (2011). Tumour necrosis factor gene polymorphism and disease prevalence. Scand J Immunol, 74, 522-47.
23. Salanti G, Amountza G, Ntzani EE, et al (2005). Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet, 13, 840-8.
24. Sethi G, Shanmugam MK, Ramachandran L, et al (2012). Multifaceted link between cancer and inflammation. Biosci Rep, 32, 1-15.
25. Suganuma M, Watanabe T, Yamaguchi K, et al (2012). Human gastric cancer development with TNF-αlpha-inducing protein secreted from Helicobacter pylori. Cancer Lett, 322, 133-8.
26. Sun SC (2012). The noncanonical NF-kappaB pathway. Immunol Rev, 246, 125-40.
27. Vujanovic NL (2011). Role of TNF superfamily ligands in innate immunity. Immunol Res, 50, 159-74.
28. Walczak H (2011). TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunol Rev, 244, 9-28.
29. Wang B, Huang G, Wang D, et al (2010a). Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol, 53, 508-18.
30. Wang B, Wang J, Zheng Y, et al (2010b). A study of TNFalpha- 238 and -308 polymorphisms with different outcomes of persistent hepatitis B virus infection in China. Pathology, 42, 674-80.
31. Wang CK, Zhang CY, Huang TR, et al (2012). Correlation between TNF-α polymorphisms and family clustering of primary liver cancer in Guangxi. Chin J of Oncol Prev and Treat, 4, 149-53.
32. Wang J, Cao C, Luo H, et al (2011). Tumour necrosis factor alpha -308G/A polymorphism and risk of the four most frequent cancers: a meta-analysis. Int J Immunogenet, 38, 311-20.
33. Wang Y, Kato N, Hoshida Y, et al (2003). Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology, 37, 65-71.
34. Wiangnon S, Kamsa-ard S, Suwanrungruang K, et al (2012). Trends in incidence of hepatocellular carcinoma, 1990-2009, Khon Kaen, Thailand. Asian Pac J Cancer Prev, 13, 1065-8.
35. Zhou P, Lv GQ, Wang JZ, et al (2011). The TNF-αlpha-238 polymorphism and cancer risk: a meta-analysis. PLoS One, 6, e22092.